BillionToOne leverages its proprietary technology, particularly the Quantitative Counting Templates (QCTs™), to enhance disease detection at a molecular level. This innovative platform allows for the detection and quantification of disease-related DNA fragments, even those that are sparse or nearly undetectable in cell-free DNA (cfDNA). By focusing on single base-pair resolution, BillionToOne's technology addresses the challenges associated with identifying small genetic variations that can lead to severe recessive conditions, such as sickle cell disease and cystic fibrosis. This capability is particularly transformative for non-invasive prenatal testing (NIPT) and liquid biopsy applications, enabling more accurate assessments of fetal risk and cancer monitoring.

In the realm of prenatal screening, BillionToOne's UNITY Screen™ stands out as the only commercially available NIPT that evaluates risks for both aneuploidies and recessive conditions from a single maternal blood draw, without requiring a paternal sample. This approach not only streamlines the testing process but also promotes equitable care for pregnant patients. Additionally, their Northstar Select™ and Northstar Response™ products enhance oncology testing by providing comprehensive genomic profiling of tumors and monitoring treatment efficacy through the quantification of circulating tumor DNA (ctDNA). Overall, BillionToOne's advanced molecular counting technology is poised to significantly improve the accuracy, efficiency, and accessibility of genetic testing in both prenatal and oncology settings.

United States

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BillionToOne

Company Details